KYMR
NASDAQ · Biotechnology
Kymera Therapeutics Inc
$127.87
-8.38 (-6.15%)
Financial Highlights (FY 2026)
Revenue
38.07M
Net Income
-302,272,288
Gross Margin
—
Profit Margin
-794.0%
Rev Growth
-5.8%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 63.8% | 63.8% |
| Operating Margin | -891.1% | -802.0% | 5.7% | 5.2% |
| Profit Margin | -794.0% | -754.3% | 4.3% | 4.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 38.07M | 40.39M | 7.83B | 9.20B |
| Gross Profit | — | — | 5.00B | 5.87B |
| Operating Income | -339,222,168 | -323,925,677 | 447.05M | 479.50M |
| Net Income | -302,272,288 | -288,641,972 | 335.40M | 415.81M |
| Gross Margin | — | — | 63.8% | 63.8% |
| Operating Margin | -891.1% | -802.0% | 5.7% | 5.2% |
| Profit Margin | -794.0% | -754.3% | 4.3% | 4.5% |
| Rev Growth | -5.8% | -5.8% | +18.7% | +14.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 10.88M | 10.88M | 1.80B | 1.98B |
| Total Equity | 5.18B | 5.18B | 3.36B | 3.32B |
| D/E Ratio | 0.00 | 0.00 | 0.53 | 0.60 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -331,146,059 | -333,781,173 | 592.59M | 664.46M |
| Free Cash Flow | — | — | 369.62M | 455.69M |